TABLE 2.
Event free survival (EFS) and overall survival (OS) for selected high-risk or relapsed Wilms tumors in the SIOP 93–01 and SIOP 2001 trial.
| SIOP 2001 | |||||
|---|---|---|---|---|---|
| Stage | Histology | N | |||
| II/III | Blastemal-type | 153 | 5-year EFS 77% (95% CI 69–86%)* | 5-year OS 82% (95% CI 74–91%) | |
| III | All high-risk histology | 141 | 2-year EFS 68% | 5-year OS 70% | |
| IV | All high-risk histology | 75 | 2-year EFS 31% | 5-year OS 35% | |
| IV | Blastemal-type | 34 | 5-year EFS 44% (95% CI 27–61) | 5-year OS 53% (95% CI 36–70%) | |
| IV | Diffuse anaplastic | 40 | 5-year EFS 28% (95% CI 13–43%) | 5-year OS 29% (95% CI 13–45%) | |
| Relapse | |||||
| Initial stage | Histology | SIOP 93–01 | |||
| I | Excluding blastemal-type and diffuse anaplastic | 33 | 5-year EFS 55% (95% CI 38–70) | 5-year OS 64% (95% CI 47–78) | |
| Relapse | SIOP 2001 | ||||
| I/II + III (no RT) | Excluding blastemal-type and diffuse anaplastic | 76 | 5-year EFS 83% (95% CI 73–90) | 5-year OS 88% (95% CI 79–94) | |
| All stages | Relapse (all histology types) | 538 | NA | 5-Year OS 56% (95% CI 51–61%) | |